Clinical Research Directory
Browse clinical research sites, groups, and studies.
PG2 Breast Cancer Evaluation in Adjuvant Medicine Study
Sponsor: PhytoHealth Corporation
Summary
Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence. Anthracycline-based regimens, including doxorubin or epilubicin, are the breast cancer adjuvant chemotherapy standards of care. Fatigue has also been identified as the most problem for breast cancer patients under adjuvant chemotherapy. In the current study, it is aimed to show that PG2 (astragalus polysaccharides) treatment among stage II/III breast patients under adjuvant EC regimen in reduction of chemotherapy-induced toxicity and encouraging compliance with chemotherapy.
Official title: PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy
Key Details
Gender
FEMALE
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
67
Start Date
2018-03-01
Completion Date
2021-08-27
Last Updated
2026-06-17
Healthy Volunteers
No
Interventions
Astragalus polysaccharides 500 mg
PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
Placebo
500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
EC Chemotherapy
Epirubicin plus Cyclophosphamide every 21 days
Locations (5)
E-Da Cancer Hospital
Kaohsiung City, Taiwan
Chang Gung Memorial Hospital, Kaohsiung Branch
Kaohsiung City, Taiwan
Chang Gung Memorial Hospital, Lovers Lake branch
Keelung, Taiwan
Chang Gung Memorial Hospital, Taipei Branch
Taipei, Taiwan
Chang Gung Memorial Hospital, Linkou Branch
Taoyuan City, Taiwan